{"id":"C2004L04916","name":"Health Insurance (Variation of Pathology Services Table) (No. 2) Regulations","slug":"health-insurance-variation-of-pathology-services-table-no-2-regulations","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"repealed","isInForce":false,"actNumber":"312 of 1990","makingDate":null,"administeringDepartment":null,"currentVersion":{"id":27722,"registerId":"commonwealth-C2004L04916-current","compilationNumber":null,"startDate":"2026-04-01","status":"Repealed","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"Health Insurance (Variation of Pathology Services Table) (No. 2) Regulations","content":"![Commonwealth Coat of Arms of Australia](image.001.jpeg)\n\nStatutory Rules 1990 No. 3121\n\n–––––––\n\nHealth Insurance (Variation of Pathology Services Table) (No. 2) Regulations\n\nI, THE GOVERNOR-GENERAL of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the Health Insurance Act 1973.\n\nDated 11 October 1990.\n\nBILL HAYDEN\n\nGovernor-General\n\nBy His Excellency’s Command,\n\nB. HOWE\n\nMinister of State for Community Services and Health\n\n–––––––––\n\nCitation\n\n1. These Regulations may be cited as the Health Insurance (Variation of Pathology Services Table) (No. 2) Regulations.\n\nCommencement\n\n2\\. These Regulations commence on 15 October 1990.\n\n \n\nVariation of the pathology services table\n\n3. The Health Insurance Act 1973 has effect as if the pathology services table were varied:\n\n(a) by inserting after rule 16 of the rules for interpretation the following heading:\n\n“PATHOLOGY SERVICES TABLE—SCHEDULE OF SERVICES AND FEES”;\n\n(b) by omitting items 1396, 1397 and 2400;\n\n(c) as the case requires:\n\n(i) by substituting for the like-numbered item; or\n\n(ii) inserting in the proper numerical position (in the case of item 2387, in Division 8);\n\neach of the items set out in Schedule 1 to these Regulations;\n\n(d) by omitting the lists of abbreviations and substituting the lists of abbreviations set out in Schedule 2 to these Regulations.\n\nRepeal\n\n4. Statutory Rules 1989 No. 198 and 1990 No. 84 are repealed.\n\n––––––––––\n\n \nSCHEDULE 1 Paragraph 4 (c)\n\nITEMS TO BE SUBSTITUTED FOR EXISTING ITEMS, OR INSERTED, IN THE PATHOLOGY SERVICES TABLE\n\n| Item No. | Pathology Service | Fees—All States |\n| -------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------- |\n| | | $ |\n| 1170 | Examination of blood film, with or without differential cell count, or differential cell count with or without examination of blood film, and if performed, any of these additional services—Direct Coombs test, tests for heterophile antibodies, cold agglutinins, examination of blood film by special stains to demonstrate Heinz bodies, parasites or iron, or examination of a blood film with alpha-naphthyl acetate esterase, chloroacetate esterase, neutrophil alkaline phosphotase, nitro blue tetrazolium, periodic acid Schiff, Sudan Black stains, or Kleihauer test for HbF on blood film, including any services specified in item 1419. SP | 13.20 |\n| 1171 | Examination of blood film, with or without differential cell count, or differential cell count with or without examination of blood film, and if performed, any of these additional services—Direct Coombs test, tests for heterophile antibodies, cold agglutinins, examination of blood film by special stains to demonstrate Heinz bodies, parasites or iron, or examination of a blood film with alpha-naphthyl acetate esterase, chloroacetate esterase, neutrophil alkaline phosphotase, nitro blue tetrazolium, periodic acid Schiff, Sudan Black stains, or Kleihauer test for HbF on blood film, including any services specified in item 1420. OP | 9.90 |\n| 1419 | Direct Coombs test, qualitative or quantitative test for cold agglutinins, or heterophile antibodies, qualitative spectroscopic examinations of blood for abnormal haemoglobins, qualitative test for red cell porphyrins and detection of metalbumin (Schumm’s test) including those services specified in items 1170 and 1172—one or more tests. SP | 11.60 |\n| 1420 | Direct Coombs test, qualitative or quantitative test for cold agglutinins, or heterophile antibodies, qualitative spectroscopic examinations of blood for abnormal haemoglobins, qualitative test for red cell porphyrins and detection of metalbumin (Schumm’s test) including those services specified in items 1171 and 1173—one or more tests. OP | 8.70 |\n| 1575 | Qualitative estimation by any method, except by reagent strip or dipstick of the following urine constituents—bilirubin, cystine (cysteine), haemoglobin, melanin (melanogen), myoglobin, porphobilinogen, porphyrins, urobilinogen or pH measurement of body fluids other than urine (excepting urine acidification test), or cryoglobulins or cryofibrinogen in plasma—one or more estimations. SP | 12.60 |\n\n \nSCHEDULE 1—continued\n\n| Item No. | Pathology Service | Fees—All States |\n| -------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------- |\n| | | $ |\n| 1576 | Qualitative estimation by any method, except by reagent strip or dipstick of the following urine constituents—bilirubin, cystine (cysteine), haemoglobin, melanin (melanogen), myoglobin, porphobilinogen, porphyrins, urobilinogen or pH measurement of body fluids other than urine (excepting urine acidification test), or cryoglobulins or cryofibrinogen in plasma—one or more estimations. OP | 9.45 |\n| 1712 | Drug assay—quantitative estimation on blood or other body fluid by any method or methods of a drug being used therapeutically for the patient from whom the specimen was taken—one estimation not elsewhere specified in the Schedule. SP | 26.50 |\n| 1713 | Drug assay—quantitative estimation on blood or other body fluid by any method or methods of a drug being used therapeutically for the patient from whom the specimen was taken—one estimation not elsewhere specified in the Schedule. OP | 19.90 |\n| 1726 | Amniotic fluid, spectrophotometric examination of, estimation of lecithin/sphingomyelin ratio, palmitic acid, phosphatidylglycerol or lamellar body phospholipid—one or more examinations or estimations. SP | 42.00 |\n| 1727 | Amniotic fluid, spectrophotometric examination of, estimation of lecithin/sphingomyelin ratio, palmitic acid, phosphatidylglycerol or lamellar body phospholipid—one or more examinations or estimations. OP | 31.50 |\n| 1738 | Alpha-feto protein, Alpha-1 antitrypsin, Alpha-2 macroglobulin, beta-2 microglobulin, C-l esterase inhibitor, Caeruloplasmin, Ferritin (unless specified in item 1752), Haptoglobins, Microalbumin (in proven diabetes mellitus), Mucin-like carcinoma associated antigen (one or more fractions), Prostate specific antigen, Prostatic Acid Phosphatase (one or more fractions), Transferrin (unless specified in item 1752), and, in the follow-up of proven malignancy, CA-125 antigen, CA-19.9 antigen, CA-15.3 antigen, Carcinoembryonic antigen, Mammary serum antigen, Neuron specific enolase, SCC Related antigen, Thyroglobulin,—quantitative estimation in serum, urine or other body fluid—one estimation. SP | 25.50 |\n\n \nSCHEDULE 1—continued\n\n| Item No. | Pathology Service | Fees—All States |\n| -------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------- |\n| | | $ |\n| 1739 | Alpha-feto protein, Alpha-1 antitrypsin, Alpha-2 macroglobulin, beta-2 microglobulin, C-l esterase inhibitor, Caeruloplasmin, Ferritin (unless specified in item 1753), Haptoglobins, Microalbumin (in proven diabetes mellitus), Mucin-like carcinoma associated antigen (one or more fractions), Prostate specific antigen, Prostatic Acid Phosphatase (one or more fractions), Transferrin (unless specified in item 1753), and, in the follow-up of proven malignancy, CA-125 antigen, CA-19.9 antigen, CA-15.3 antigen, Carcinoembryonic antigen, Mammary serum antigen, Neuron specific enolase, SCC Related antigen, Thyroglobulin,—quantitative estimation in serum, urine or other body fluid—one estimation. OP | 19.15 |\n| 1771 | Red cell folate and serum B12 and, if required, serum folate, to a maximum of three estimations in any 12-month period. OP | 43.15 |\n| 1791 | Acetoacetate, alcohol, aminoacids, ammonia, angiotensin converting enzyme, betahydroxybutyrate, cholinesterase, cystine (cysteine), histamine, hydroxyindoleacetic acid, hydroxyproline, lactate, neonatal bilirubin (one or more fractions), oxalate, pyruvate, seratonin, xylose, zinc—one quantitative estimation. SP | 31.50 |\n| 1792 | Acetoacetate, alcohol, aminoacids, ammonia, angiotensin converting enzyme, betahydroxybutyrate, cholinesterase, cystine (cysteine), histamine, hydroxyindoleacetic acid, hydroxyproline, lactate, neonatal bilirubin (one or more fractions), oxalate, pyruvate, seratonin, xylose, zinc—one quantitative estimation. OP | 23.65 |\n| 1959 | Porphyrins (one or more fractions), Catecholamines (one or more fractions), Hydroxy Methoxy Mandelic Acid (HMMA), Homovanillic Acid (HVA), Metanephrines, Methoxy Hydroxy Phenylethylene Glycol (MHPG), Phenyl Acetic Acid (PAA)— quantitative including any qualitative estimations—one or more estimations. SP | 51.00 |\n| 1960 | Porphyrins (one or more fractions), Catecholamines (one or more fractions), Hydroxy Methoxy Mandelic Acid (HMMA), Homovanillic Acid (HVA), Metanephrines, Methoxy Hydroxy Phenylethylene Glycol (MHPG), Phenyl Acetic Acid (PAA)— quantitative including any qualitative estimations—one or more estimations. OP | 38.25 |\n\n \nSCHEDULE 1—continued\n\n| Item No. | Pathology Service | Fees—All States |\n| -------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------- |\n| | | $ |\n| 2021 | Hormones and hormone binding proteins, qualitative estimation by any method of: ACTH, Aldosterone, Androstenedione, C-peptide, Calcitonin, Cortisol, Cyclic AMP, DHEAS, 11-Deoxycortisol, Dihydrotestosterone, FSH, Gastrin, Glucagon, Growth Hormone, Medroxyprogesterone, Insulin, LH, Oestradiol, Oestriol, Oestrone, Progesterone, Prolactin, PTH, Renin, Sex hormone binding globulin, Somatomedin C(IgF1), free or total Testosterone, TSH (where not requested as part of a thyroid function test), Urine steroid fraction or fractions, Vasoactive intestinal peptide, Vasopressin (anti-diuretic hormone)—one estimation. SP | 36.50 |\n| 2024 | Hormones and hormone binding proteins, qualitative estimation by any method of: ACTH, Aldosterone, Androstenedione, C-peptide, Calcitonin, Cortisol, Cyclic AMP, DHEAS, 11-Deoxycortisol, Dihydrotestosterone, FSH, Gastrin, Glucagon, Growth Hormone, Hydroxyprogesterone, Insulin, LH, Oestradiol, Oestriol, Oestrone, Progesterone, Prolactin, PTH, Renin, Sex hormone binding globulin, Somatomedin C(IgF1), free or total Testosterone, TSH (where not requested as part of a thyroid function test), Urine steroid fraction or fractions, Vasoactive intestinal peptide, Vasopressin (anti-diuretic hormone)—one estimation. OP | 27.40 |\n| 2032 | Five estimations specified in item 2024. OP | 75.00 |\n| 2087 | The cultural examination and microscopical examination when indicated (including the detection of antigens not elsewhere specified in the Schedule) to determine the presence of pathogenic micro-organisms, including fungi but excluding viruses, from nasal swabs, throat swabs, eye swabs and ear swabs, including pathogen identification and antibiotic sensitivity testing, including any additional services specified in item 2083—one or more sites. SP | 25.00 |\n| 2088 | The cultural examination and microscopical examination when indicated (including the detection of antigens not elsewhere specified in the Schedule) to determine the presence of pathogenic micro-organisms, including fungi but excluding viruses, from nasal swabs, throat swabs, eye swabs and ear swabs, including pathogen identification and antibiotic sensitivity testing, including any additional services specified in item 2084—one or more sites. OP | 18.75 |\n| 2089 | Microscopical and cultural examination (including the detection of antigens not elsewhere specified in the Schedule) to determine the presence of pathogenic micro-organisms, including fungi but excluding viruses, from the following—skin or other superficial sites, urethra, vagina, cervix or rectum (except for faecal pathogens) or specimens of sputum (except when part of item 2119), including pathogenic identification and antibiotic sensitivity testing, including any services specified in items 2083 and 2087—one or more examinations on one or more specimens. SP | 36.50 |\n\n \nSCHEDULE 1—continued\n\n| Item No. | Pathology Service | Fees—All States |\n| -------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------- |\n| | | $ |\n| 2090 | Microscopical and cultural examination (including the detection of antigens not elsewhere specified in the Schedule) to determine the presence of pathogenic micro-organisms, including fungi but excluding viruses, from the following: skin or other superficial sites, urethra, vagina, cervix or rectum (except for faecal pathogens) or specimens of sputum (except when part of item 2120), including pathogenic identification and antibiotic sensitivity testing, including any services specified in items 2084 and 2088—one or more examinations on one or more specimens. OP | 27.40 |\n| 2098 | Microscopical and cultural examination (including the detection of antigens not elsewhere specified in the Schedule) of postoperative wounds, aspirations of body cavities, synovial fluid, CSF and operative or biopsy specimens for the presence of pathogenic micro-organisms, including fungi but excluding viruses, involving aerobic and anaerobic culture and the use of different culture media and including pathogen identification and antibiotic sensitivity testing, including any services specified in items 2083, 2087 anti 2089—one or more sites. SP | 49.50 |\n| 2099 | Microscopical and cultural examination (including the detection of antigens not elsewhere specified in the Schedule) of postoperative wounds, aspirations of body cavities, synovial fluid, CSF and operative or biopsy specimens for the presence of pathogenic micro-organisms, including fungi but excluding viruses, involving aerobic and anaerobic culture and the use of different culture media and including pathogen identification and antibiotic sensitivity testing, including any services specified in items 2084, 2088 and 2090—one or more sites. OP | 37.15 |\n| 2229 | All serological tests performed for the identification of the agent causing acute Hepatitis, which must include Hepatitis B surface antigen, Hepatitis B core antibody and Hepatitis A IgM antibody tests and those services specified in items 2221, 2223 and 2231. SP | 47.50 |\n| 2230 | All serological tests performed for the identification of the agent causing acute Hepatitis, which must include Hepatitis B surface antigen, Hepatitis B core antibody and Hepatitis A IgM antibody tests and those services specified in items 2222, 2224 and 2232. OP | 35.65 |\n| 2258 | Immunoglobulin E (total), quantitative estimation by any method or methods, with a maximum of two estimations in any 12-month period. OP | 25.15 |\n| 2261 | Antinuclear antibodies, detection in serum or other body fluids, including quantitation if required. SP | 31.50 |\n| 2262 | Antinuclear antibodies, detection in serum or other body fluids, including quantitation if required. OP | 23.65 |\n\n \nSCHEDULE 1—continued\n\n| Item No. | Pathology Service | Fees—All States |\n| -------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------- |\n| | | $ |\n| 2263 | Measurement of DNA binding (by Farr or equivalent assay, but excluding the Crithidia method) performed only where a positive antinuclear antibody titre of 1:40 or greater has been obtained. SP | 38.50 |\n| 2266 | Measurement of DNA binding (by Farr or equivalent assay, but excluding the Crithidia method) performed only where a positive antinuclear antibody titre of 1:40 or greater has been obtained. OP | 28.85 |\n| 2315 | Functional tests for leucocytes, including use of all appropriate techniques (except E. rosette technique or similar) and any test specified in Division 1—Haematology in the Schedule. SP | 66.00 |\n| 2316 | Functional tests for leucocytes, including use of all appropriate techniques (except E. rosette technique or similar) and any test specified in Division 1—Haematology in the Schedule. OP | 49.50 |\n| 2343 | Cytological examination including serial examinations for malignant cells of body fluids, sputum (single specimen), urine (single specimen), washings or brushings not specified in item 2340 and any histopathology service performed on that cytology specimen—one or more examinations. SP | 38.00 |\n| 2344 | Cytological examination including serial examinations for malignant cells of body fluids, sputum (single specimen), urine (single specimen), washings or brushings not specified in item 2341 and any histopathology service performed on that cytology specimen—one or more examinations. OP | 28.50 |\n| 2355 | Cytological examination of material obtained from a patient by fine needle aspiration of solid tissue or tissues where the aspiration is performed by a recognised pathologist; or where a recognised pathologist attends the aspiration and performs cytological examination during the attendance. SP | 89.00 |\n| 2356 | Cytological examination of material obtained from a patient by fine needle aspiration of solid tissue or tissues where the aspiration is performed by a recognised pathologist; or where a recognised pathologist attends the aspiration and performs cytological examination during the attendance. OP | 66.75 |\n| 2387 | Seminal examination for presence of spermatozoa. | 5.85 |\n| 2396 | Microscopical examination of gram-stained film. | 7.40 |\n| 2397 | Chemical tests for occult blood in faeces by reagent stick, strip, tablet or similar method. | 1.95 |\n\n––––––––––\n\n \nSCHEDULE 2 Paragraph 4 (d)\n\nLISTS OF ABBREVIATIONS\n\nA. ABBREVIATIONS FOR GROUPS OF TESTS\n\n| Group | EstimationsIncluded in Group | Abbreviation | Item Numbers |\n| -------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------ | ------------ |\n| Cardiac Enzymes | Lactate dehydrogenase (LDH) Aspartate aminotransferase (AST) and Creatine kinase (CK) | CE | 1562,1563 |\n| Coagulation Studies | Prothrombin Time, activated partial thromboplastin time and 2 or more of the following tests: bleeding time, thrombin clotting time, fibrinogen degradation products, fibrin monomer, D-dimer, Factor XIII screening tests. | COAG | 1527,1528 |\n| Electrolytes | Sodium (NA),Potassium (K),Chloride (CL) andBicarbonate (HC03) | E | 1564,1565 |\n| Lipid Studies | Cholesterol (CHOL) and Triglycerides (TRIG) | FATS | 1560,1561 |\n| Liver Function Tests | Alkaline phosphatase (ALP), Alanine aminotransferase (ALT), Aspartate aminotransferase (AST) Albumin (ALB), Bilirubin (BIL), Gamma glutamyl transpeptidase (GGT), Lactate dehydrogenase (LDH) and Protein (PROT) | LFT | 1571,1572 |\n| Syphilis Serology | Rapid plasma reagin test (RPR) or venereal disease research laboratory test (VDRL) and Treponema pallidum haemagglutin test (TPHA) or Fluorescent Treponemal antibody-absorption test (FTA) | STS | 2183,2184 |\n\n \n\nSCHEDULE 2—continued\n\nB. ABBREVIATIONS FOR INDIVIDUAL TESTS\n\nThe abbreviations are listed alphabetically within the following Divisions:\n\n1\\. HAEMATOLOGY\n\n2\\. CHEMICAL PATHOLOGY\n\n3\\. MICROBIOLOGY\n\n4\\. IMMUNOLOGY\n\n5\\. HISTOPATHOLOGY\n\n6\\. CYTOPATHOLOGY\n\n7\\. CYTOGENETICS\n\n8\\. INFERTILITY & PREGNANCY TESTS\n\n```html\n

Approved Item Name of Test in Schedule

Abbreviation

Item Numbers

DIVISION 1—HAEMATOLOGY

Antithrombin III

ATH

1531, 1532

Abnormal haemoglobins—spectroscopic examination of blood

AH

1419, 1420

Bleeding Time

BT

1521, 1522

Blood coagulation factors—quantitative assays:

Von Willebrand’s factor antigen

VWA

1541, 1542

Von Willebrand’s factor

VWF

1541, 1542

Fletcher Factor

FF

1541, 1542

Fitzgerald Factor

FGF

1541, 1542

Passovy Factor

PF

1541, 1542

Factor II

FII

1541, 1542

Factor V

FV

1541, 1542

Factor VII

FVII

1541, 1542

Factor VIII

FVIII

1541, 1542

Factor IX

FIX

1541, 1542

Factor X

FX

1541, 1542

Factor XI

FXI

1541, 1542

Factor XII

FXII

1541, 1542

Factor XIII

FXIII

1541, 1542

Blood Film

BF

1170, 1171

Blood Group Antibodies

BGA

1417, 1418

Blood Grouping—ABO and Rh (D antigen)

BG

1187, 1188

Blood Group and blood group antibodies (group and hold)

BGAB

1196, 1197

Blood Group Systems (Duffy, Kell, M & N factors, Rh phenotypes)

BGS

1192, 1193

Bone Marrow Examination—Trephine

BMET

1181, 1182

Bone Marrow Examination—Aspirate

BMEA

1183, 1184

Carboxyhaemaglobin

COHB

1419, 1420

Coagulation Time

CT

1521, 1522

Cold Agglutinins

CAG

1419, 1420

Compatibility testing

XMAT

1198, 1199

C-reactive protein

CRP

1163, 1164

Differential Cell Count

DIFF

1170, 1171

Direct Coombs test

CMBS

1419, 1420

D-dimer test

DD

1521, 1522

Erythrocyte Count

RCC

1163, 1164

Erythrocyte Metabolic Enzymes

ERYM

1176, 1177

Erythrocyte Sedimentation Rate

ESR

1163, 1164

\n```\n\n \nSCHEDULE 2—continued\n\n```html\n

Approved Item Name of Test in Schedule

Abbreviation

Item Numbers

Erythrocyte Haemolysis

ERYH

1176, 1177

Euglobulin clot lysis time

ECLT

1531, 1532

Fibrinogen Degradation Products

FDP

1521, 1522

Fibrin Monomer

FM

1521, 1522

Fibrinogen

FIB

1521, 1522

Full Blood Examination

FBE

1172, 1173

Haemoglobin Estimation

HB

1163, 1164

Haemoglobinopathy tests

HMGP

1179, 1180

Heparin Cofactor II

HRNC

1531, 1532

Heparin Estimation

HEPR

1539, 1540

Heterophile Antibodies (Infectious Mononucleosis Test)

IM

1419, 1420

Leucocyte Count

WCC

1163, 1164

Lupus Anticoagulant

LUPA

1531, 1532

Metalbumin detection (Schumm’s test)

SCHM

1419, 1420

Plasminogen

PLAS

1531, 1532

Partial Thromboplastin Time

PTT

1521, 1522

Platelet Aggregation

PLTG

1535, 1538

Platelet Count

PLTC

1163, 1164

Protein C

PROC

1531, 1532

Protein S

PROS

1531, 1532

Prothrombin Time

PT

1521, 1522

Red Cell Porphyrins—qualitative test

RCP

1419, 1420

Reticulocyte Count

RETC

1163, 1164

Test for Factor XIII Deficiency

F13D

1521, 1522

Thalassaemia Studies

TS

1179, 1180

Thrombin Time

TT

1521, 1522

Viscosity of blood or plasma

VISC

1163, 1164

DIVISION 2—CHEMICAL PATHOLOGY

Acetoacetate

ACAT

1791, 1792

Alanine Aminotransferase

ALT

1558, 1559

Albumin

ALB

1558, 1559

Alcohol (Ethanol)

ETOH

1791, 1792

Alkaline Phosphatase

ALP

1558, 1559

Alkaline Phosphatase Isoenzymes

ALPI

1734, 1735

Aminoacids

AMNA

1791, 1792

Amniotic Fluid Examination

AFE

1726, 1727

Ammonia

NH3

1791, 1792

Amylase

AMS

1558, 1559

Angiotensin converting enzyme

ACE

1791, 1792

Aspartate Aminotransferase

AST

1558, 1559

Beta Hydroxybutyrate

BHYB

1791, 1792

Bicarbonate

HCO3

1558, 1559

Bilirubin (all Fractions)

BILI

1558, 1559

Bilirubin (Neonatal)

BILN

1791, 1792

Blood Gases

GAS

1590, 1591

Calcium (total, dialysed or ionized)

CA

1558, 1559

Calculus Analysis

CALC

1595, 1596

Catecholamines

CAT

1959, 1960

Cholinesterase

CHSE

1791, 1792

Chloride

CL

1558, 1559

\n```\n\n \nSCHEDULE 2—continued\n\n| Approved Item Name of Test in Schedule | Abbreviation | Item Numbers |\n| ------------------------------------------------------------------------------------ | ------------ | ------------ |\n| Cholesterol | CHOL | 1558, 1559 |\n| Cystine (Cysteine) | CYST | 1791, 1792 |\n| Creatine Kinase | CK | 1558, 1559 |\n| Creatine Kinase Isoenzymes | CKI | 1558, 1559 |\n| Creatine Kinase Isoenzymes—Quantitative or Qualitative estimation by electrophoresis | CKIE | 1734, 1735 |\n| Creatinine | C | 1558, 1559 |\n| Cryoglobulins | CGLB | 1575, 1576 |\n| Cryofibrinogen | CFIB | 1575, 1576 |\n| Dexamethazone Suppression test | DEXA | 2021, 2024 |\n| Drug or Chemical Assays—Overdose | DRGO | 1598, 1599 |\n| Drug Assays—Drug abuse treatment programme including urinary drug screen | DRGA | 1627, 1628 |\n| Drug Assays—Therapeutic: | | |\n| Antibiotics or antimicrobial chemotherapeutic agents (see under MICROBIOLOGY) | | |\n| Acetylated sulphadimidine | ASUL | 1712, 1713 |\n| Amiodarone | AMIO | 1712, 1713 |\n| Amitriptyline | AMIT | 1712, 1713 |\n| Amylobarb | AMYL | 1712, 1713 |\n| Barbitone | BARB | 1712, 1713 |\n| Bromide | BRMD | 1712, 1713 |\n| Butobarb | BUTO | 1712, 1713 |\n| Carbamazepine (Tegretol) | CARB | 1712, 1713 |\n| Chloral Hydrate | CHHY | 1712, 1713 |\n| Chlorazepate | CHZP | 1712, 1713 |\n| Chloropromazine | CHLO | 1712, 1713 |\n| Chloroquine | CLOQ | 1712, 1713 |\n| Cimetidine | CMTD | 1712, 1713 |\n| Clobozam | CLOB | 1712, 1713 |\n| Clonazepam (Rivotril) | CLON | 1712, 1713 |\n| Cylosporin A | CLSA | 1712, 1713 |\n| Desethyl Amiodarone | DEAM | 1712, 1713 |\n| Desipramine | DESI | 1712, 1713 |\n| Diazepam | DIAZ | 1712, 1713 |\n| Digoxin | DIG | 1712, 1713 |\n| Diphenylhydantoin (Dilantin) | DIL | 1712, 1713 |\n| Disopyramide (Rythmodan) | DISO | 1712, 1713 |\n| Doxepin | DOXE | 1712, 1713 |\n| Ethosuximide (Zarontin) | ETHO | 1712, 1713 |\n| Flecainide | FLEC | 1712, 1713 |\n| Hydroxychloriquine | HOCQ | 1712, 1713 |\n| Imipramine | IMIP | 1712, 1713 |\n| Lignocaine | LIGN | 1712, 1713 |\n| Methadone | MTDN | 1712, 1713 |\n| Methotrexate | MTTA | 1712, 1713 |\n| Methsuximide | MSUX | 1712, 1713 |\n| Metronidazole | MRDZ | 1712, 1713 |\n| Mexilitine (Mexitil) | MEX | 1712, 1713 |\n| N Acetyl Procainamide | NAPC | 1712, 1713 |\n| N Desalkyl Clobazan | NDAC | 1712, 1713 |\n\n \nSCHEDULE 2—continued\n\n| Approved Item Name of Test in Schedule | Abbreviation | Item Numbers |\n| -------------------------------------------------------------------------------------------------- | ------------ | ------------ |\n| N Desalkyldothiepin | NDOT | 1712, 1713 |\n| N Desalkyl Doxepin | NDAD | 1712, 1713 |\n| Nitrazepam | NITR | 1712, 1713 |\n| Nordothiepin | NDIP | 1712, 1713 |\n| Nortriptyline | NORT | 1712, 1713 |\n| Oxazepam | OXAZ | 1712, 1713 |\n| Paracetamol | PARA | 1712, 1713 |\n| Paraquat | PARQ | 1712, 1713 |\n| Pentabarb | PENT | 1712, 1713 |\n| Perhexiline | PHEX | 1712, 1713 |\n| Phenobarbitone | PHBA | 1712, 1713 |\n| Phensoximide | PHEN | 1712, 1713 |\n| Phenytoin | PHEY | 1712, 1713 |\n| Prednisolone | PRED | 1712, 1713 |\n| Primidone | PRIM | 1712, 1713 |\n| Procainamide | PCAM | 1712, 1713 |\n| Prominal | PROM | 1712, 1713 |\n| Propanolol | PPNO | 1712, 1713 |\n| Quinalbarb | QUIB | 1712, 1713 |\n| Quinine | QNN | 1712, 1713 |\n| Quinidine | QUIN | 1712, 1713 |\n| Silicylate-Asprin | SALI | 1712, 1713 |\n| Sotalol | SALL | 1712, 1713 |\n| Stellazine | STEL | 1712, 1713 |\n| Sulphadimidine | SPDD | 1712, 1713 |\n| Sulthiame (Ospolot) | SUL | 1712, 1713 |\n| Theophylline | THEO | 1712, 1713 |\n| Thiopentone | TOPO | 1712, 1713 |\n| Thioridazine | THIO | 1712, 1713 |\n| Tocainide | TOCN | 1712, 1713 |\n| Trimipramine | TRIM | 1712, 1713 |\n| Valproate (Epilim) | VALP | 1712, 1713 |\n| Vancomycin | VAN | 1712, 1713 |\n| Warfarin | WFR | 1712, 1713 |\n| Therapeutic drugs which are not listed above must be written in full | | |\n| Electrophoresis | | |\n| To demonstrate protein classes or presence and amount of paraprotein classes | EPP1 | 1734, 1735 |\n| To demonstrate protein classes or presence and amount of paraprotein classes—concurrent collection | EPP2 | 1736, 1737 |\n| Elements: | | |\n| Aluminium | AL | 1871, 1872 |\n| Arsenic | AS | 1871, 1872 |\n| Beryllium | BE | 1871, 1872 |\n| Cadmium | CD | 1871, 1872 |\n| Chromium | CR | 1871, 1872 |\n| Copper | CU | 1871, 1872 |\n| Gold | AU | 1871, 1872 |\n| Lead | PB | 1895, 1896 |\n\n \nSCHEDULE 2—continued\n\n| Approved Item Name of Test in Schedule | Abbreviation | Item Numbers |\n| ---------------------------------------- | ------------ | ------------ |\n| Manganese | MN | 1871, 1872 |\n| Mercury | HG | 1871, 1872 |\n| Nickel | NI | 1871, 1872 |\n| Selenium | SE | 1871, 1872 |\n| Strontium | SR | 1871, 1872 |\n| Zinc | ZN | 1791, 1792 |\n| Enzyme assays of solid tissue or tissues | ENZS | 1969, 1970 |\n| Faecal Fat | FFAT | 1963, 1964 |\n| Faecal Heamoglobin (chemical test) | FHC | 1577, 1578 |\n| Faecal Heamoglobin (immunological test) | FHI | 1579, 1580 |\n| Faecal Porphyrins (qualitative test) | FPR | 1577, 1578 |\n| Faecal Reducing Substances | FRS | 1577, 1578 |\n| Fructosamine | FRUC | 1558, 1559 |\n| Gamma Glutamyl Transpeptidase | GGT | 1558, 1559 |\n| Globulin | GLOB | 1558, 1559 |\n| Glucose | GLUC | 1558, 1559 |\n| Glucose Tolerance Test | GTT | 1558, 1559 |\n| Glycosylated Haemoglobin (Hb Ale) | GHB | 2043, 2044 |\n| HDL Cholesterol | HDLC | 2039, 2040 |\n| Hormones: | | |\n| Adrenocorticotrophic hormone | ACTH | 2021, 2024 |\n| Aldosterone | ALDS | 2021, 2024 |\n| Androstenedione | ANDR | 2021, 2024 |\n| C-Peptide | CPEP | 2021, 2024 |\n| Calcitonin | CALT | 2021, 2024 |\n| Cortisol | CORT | 2021, 2024 |\n| Cyclic AMP | CAMP | 2021, 2024 |\n| Dehydroepiandrosterone sulphate | DHEA | 2021, 2024 |\n| Dihydrotestosterone | DHTS | 2021, 2024 |\n| Follicular Stimulating Hormone | FSH | 2021, 2024 |\n| Gastrin | GAST | 2021, 2024 |\n| Glucagon | GLGO | 2021, 2024 |\n| Growth Hormone | GH | 2021, 2024 |\n| Hormone Receptor Assay | HRA | 2037, 2038 |\n| Hydroxyprogesterone | OHP | 2021, 2024 |\n| Insulin | INS | 2021, 2024 |\n| Luteinizing Hormone | LH | 2021, 2024 |\n| Oestradiol | E2 | 2021, 2024 |\n| Oestriol | E3 | 2021, 2024 |\n| Oestrone | E1 | 2021, 2024 |\n| Parathyroid Hormone | PTH | 2021, 2024 |\n| Progesterone | PROG | 2021, 2024 |\n| Prolactin | PROL | 2021, 2024 |\n| Renin | REN | 2021, 2024 |\n| Sex Hormone Binding Globulin | SHBG | 2021, 2024 |\n| Somatomedin | SOMA | 2021, 2024 |\n| Testosterone | TES | 2021, 2024 |\n| Thyroid Stimulating Hormone | TSH | 2021, 2024 |\n| Urine Steroid Fraction or Fractions | USF | 2021, 2024 |\n| Vasoactive Intestinal Peptide | VIP | 2021, 2024 |\n| Vasopressin | ADH | 2021, 2024 |\n| 11 Deoxycortisol | DCOR | 2021, 2024 |\n\n \nSCHEDULE 2—continued\n\n| Approved Item Name of Test in Schedule | Abbreviation | Item Numbers |\n| ------------------------------------------------------------ | ------------ | ------------ |\n| HIAA (Hydroxyindoleacetic acid) | HIAA | 1791, 1792 |\n| Histamine | HIAM | 1791, 1792 |\n| HMMA (Hydroxy Methoxy Mandelic acid previously known as VMA) | HMMA | 1959, 1960 |\n| HVA (Homovanillic acid) | HVA | 1959, 1960 |\n| Hydroxyproline | HYDP | 1791, 1792 |\n| Intestinal disaccharidases | INTD | 1969, 1970 |\n| Iron Studies (Iron, Transferrin and Ferritin) | IS | 1752, 1753 |\n| Lactate | LACT | 1791, 1792 |\n| Lactate Dehydrogenase | LDH | 1558, 1559 |\n| Lactate Dehydrogenase Isoenzymes | LDI | 1734, 1735 |\n| Lamellar Body Phospholipid | LBPH | 1726, 1727 |\n| Lecithin/Sphingomyelin Ratio (Amniotic fluid) | LS | 1726, 1727 |\n| Lipase | LIP | 1558, 1559 |\n| Lithium | LI | 1558, 1559 |\n| Magnesium | MG | 1558, 1559 |\n| Metanephrines | MNEP | 1959, 1960 |\n| MHPG (Methoxy Hydroxy Phenyethylene Glycol) | MHPG | 1959, 1960 |\n| Osmolality, Serum or Urine | OSML | 1583, 1584 |\n| Oxalate | OXAL | 1791, 1792 |\n| PAA (Phenyl Acetic Acid) | PAA | 1959, 1960 |\n| Palmitic acid in amniotic fluid | PALM | 1726, 1727 |\n| pH measurement of body fluids other than urine | PH | 1575, 1576 |\n| Phosphate | PHOS | 1558, 1559 |\n| Phosphatidylglycerol | PTGL | 1726, 1727 |\n| Porphyrins (quantitative test, one or more fractions) | PR | 1959, 1960 |\n| Potassium | K | 1558, 1559 |\n| Protein (Total) | PROT | 1558, 1559 |\n| Protein-Quantitative Estim. of Specific Protein: | | |\n| Alpha feto protein | AFP | 1738, 1739 |\n| Alpha-1 antitrypsin | AAT | 1738, 1739 |\n| Alpha-2 macroglobulin | AMAC | 1738, 1739 |\n| Beta-2 microglobulin | BMIC | 1738, 1739 |\n| C-l esterase inhibitor | CEI | 1738, 1739 |\n| Caeruloplasmin | CPLS | 1738, 1739 |\n| Ferritin | FERR | 1738, 1739 |\n| Haptoglobins | HGLB | 1738, 1739 |\n| Microalbumin | MALB | 1738, 1739 |\n| Transferrin | TRAN | 1738, 1739 |\n| Pyruvate | PVTE | 1791, 1792 |\n| Red Cell Folate and Serum B12 and, if required, Serum Folate | RCF | 1770, 1771 |\n| Seratonin | SHT | 1791, 1792 |\n| Serum B12 | B12 | 1768, 1769 |\n| Serum Folate | FOL | 1768, 1769 |\n| Snake Venom | HISS | 1598, 1599 |\n| Sodium | NA | 1558, 1559 |\n| Synacthen Stimulation Test | SYNS | 2021, 2024 |\n| Thyroid Function Tests | TFT | 1983, 1984 |\n\n \nSCHEDULE 2—continued\n\n```html\n

Approved Item Name of Test in Schedule

Abbreviation

Item Numbers

Thyroid Stimulating Hormone (where not requested as part of a TFT)

TSH

2021, 2024

Thyrotrophin Releasing Hormone Test

TRH

1985, 1986

Triglycerides

TRIG

1558, 1559

Tumour Markers:

CA-125 antigen

C125

1738, 1739

CA-19.9 antigen

CA19

1738, 1739

CA-15.3 antigen

CA15

1738, 1739

Carcinoembryonic antigen

CEA

1738, 1739

Mammary Serum antigen

MSA

1738, 1739

Mucin-like carcinoma-associated antigen

MCA

1738, 1739

Neuron-specific enolase

NSEN

1738, 1739

Prostate-specific antigen

PSA

1738, 1739

Prostatic acid phosphatase—one or more fractions

ACP

1738, 1739

SCC-related antigen

SCCA

1738, 1739

Thyroglobulin

TGL

1738, 1739

Urate

URAT

1558, 1559

Urea

U

1558, 1559

Urine Bilirubin

UBIL

1575, 1576

Urine Cystine (Cysteine)

UCYS

1575, 1576

Urine Haemoglobin

UHB

1575, 1576

Urine Melanin (Melanogen)

UML

1575, 1576

Urine Myoglobin

UMY

1575, 1576

Urine Porphobilinogen

UPG

1575, 1576

Urine Porphyrins (qualitative test)

UPR

1575, 1576

Urine Urobilinogen

UUB

1575, 1576

Vitamin, Quantitative Estimation of Vitamins A, B1, B2, B3, B6, C or E

VIT

1780, 1783

Vitamin D

VITD

1786, 1787

Xylose

XYL

1791, 1792

DIVISION 3—MICROBIOLOGY

Antibiotic and antimicrobial chemotherapeutic agents, quantitative assay

QAA

2235, 2236

Blood Culture

BC

2123, 2124

Cultural Examination of faeces

FCS

2117, 2118

Herpes Simplex Virus Investigation by Cultural Methods

HSVC

2139, 2140

Chlamydia Investigation by Cultural Methods

CHLC

2139, 2140

Microbial Antibody Testing:

(IgG, IgM, IgA or Total antibodies may be tested against various organisms and are indicated by placing the letter G, M, A or T respectively on the end of the 3-letter abbreviation)

Actinomycetes

ACT

2181, 2182

Adenovirus

ADE

2181, 2182

Aspergillus

ASP

2181, 2182

Avian precipitins (Bird Fancier’s Disease)

APP

2181, 2182

Blastomyces

BLM

2181, 2182

Bordetella pertussis

BOR

2181, 2182

Borrelia Berghoffer

BOB

2181, 2182

Brucella

BRU

2181, 2182

\n```\n\n \nSCHEDULE 2—continued\n\n| Approved Item Name of Test in Schedule | Abbreviation | Item Numbers |\n| --------------------------------------------------------- | ------------ | ------------ |\n| Campylobacter Jejuni | CAM | 2181, 2182 |\n| Candida | CAN | 2181, 2182 |\n| Chlamydia | CHL | 2181, 2182 |\n| Coccidioides | CCC | 2181, 2182 |\n| Coxsackie Bl-6 | COX | 2181, 2182 |\n| Cryptococcus | CRY | 2181, 2182 |\n| Cytomegalovirus | CMV | 2181, 2182 |\n| Cytomegalovirus Serology in Pregnancy | CMVP | 2145, 2146 |\n| Dengue | DEN | 2181, 2182 |\n| Diphtheria | DIP | 2181, 2182 |\n| Echinococcus | ECC | 2181, 2182 |\n| Echo-coxsackie group | ECH | 2181, 2182 |\n| Entamoeba histolytica | AMO | 2181, 2182 |\n| Epstein Barr Virus | EBV | 2181, 2182 |\n| Fluorescent Treponemal antibody—absorption test (FTA-ABS) | FTA | 2181, 2182 |\n| Haemophilus | HUS | 2181, 2182 |\n| Hepatitis delta antibody—Anti-delta | HDA | 2181, 2182 |\n| Histoplasma | HIP | 2181, 2182 |\n| Hydatid | HYD | 2181, 2182 |\n| Influenza A | FLA | 2181, 2182 |\n| Influenza B | FLB | 2181, 2182 |\n| Legionella pneumophila—Serogroup 1 | LP1 | 2181, 2182 |\n| Legionella pneumophila—Serogroup 2 | LP2 | 2181, 2182 |\n| Leishmaniasis | LEI | 2181, 2182 |\n| Leptospira | LEP | 2181, 2182 |\n| Listeria | LIS | 2181, 2182 |\n| Measles | MEA | 2181, 2182 |\n| Micropolyspora faeni | MIC | 2181, 2182 |\n| Mumps | MUM | 2181, 2182 |\n| Murray Valley Encephalitis | MVE | 2181, 2182 |\n| Mycoplasma pneumoniae | MYC | 2181, 2182 |\n| Neisseria gonorrhoea | GON | 2181, 2182 |\n| Newcastle Disease | NCD | 2181, 2182 |\n| Parainfluenza 1 | PF1 | 2181, 2182 |\n| Parainfluenza 2 | PF2 | 2181, 2182 |\n| Parainfluenza 3 | PF3 | 2181, 2182 |\n| Paratyphi | PTY | 2181, 2182 |\n| Pertussis | PER | 2181, 2182 |\n| Pneumococcus | PCC | 2181, 2182 |\n| Poliomyelitis | PLO | 2181, 2182 |\n| Proteus OX 19 | POX | 2181, 2182 |\n| Proteus OXK | POK | 2181, 2182 |\n| Q fever | QFF | 2181, 2182 |\n| Rapid Plasma Reagin test | RPR | 2181, 2182 |\n| Respiratory Syncytial Virus | RSV | 2181, 2182 |\n| Ross River Virus | RRV | 2181, 2182 |\n| Rubella | RUB | 2181, 2182 |\n| Rubella Serology in Pregnancy | RUBP | 2145, 2146 |\n| Salmonella typhi (H) | SAH | 2181, 2182 |\n| Salmonella typhi (O) | SAO | 2181, 2182 |\n\n \nSCHEDULE 2—continued\n\n```html\n

Approved Item Name of Test in Schedule

Abbreviation

Item Numbers

Schistosoma

STO

2181, 2182

Streptococcal Serology—Anti-D Nase B titre

ADNB

2181, 2182

Streptococcal Serology—Anti streptolysin O titre

ASOT

2181, 2182

Tetanus

TET

2181, 2182

Thermoactinomyces vulgaris

THE

2181, 2182

Thermopolyspora

TPS

2181, 2182

Toxocara

TOC

2181, 2182

Toxoplasma

TOX

2181, 2182

Toxoplasma Serology in Pregnancy

TOXP

2145, 2156

Treponema pallidum haemagglutin test

TPHA

2181, 2182

Trichonosis

TOS

2181, 2182

Typhus, Weil-Felix

TYP

2181, 2182

Venereal Disease Research Laboratory (VDRL)

VDRL

2181, 2182

Yersinia enterocolytica

YER

2181, 2182

Microbial antibody tests which are not listed above must be written in full

Hepatitis Serology:

Hepatitis Serology in Acute Hepatitis

HEP

2229, 2230

Hepatitis B Serology in follow up of proven Hepatitis B

Hepatitis B Surface antigen HBsAg

HEPB

2231, 2232

HBSA

2221, 2222

Hepatitis B Serology to define immune status

HEPI

2223, 2224

Microbial Antigen Testing:

Chlamydia

CHLY

2133, 2134

Herpes Simplex Virus

HSV

2135, 2136

CSF antigens—Haemophilus influenzae, Streptococcus Pneumoniae, Neisseria Menigitidis, Group B Streptococcus

CSFA

2129, 2130

Cryptococcal antigen

CRYN

2129, 2130

RSV—Respiratory Syncytial Virus

RSVN

2129, 2130

Varicella Zoster

VCZN

2129, 2130

Microscopic examination of material other than blood

M

2083, 2084

Microscopic examination of faeces for parasites

OCP

2085, 2086

Microscopy and culture of material from nose, throat, eye and ear

MCS1

2087, 2088

Microscopy and culture of material from skin, superficial sites, urethra, vagina, cervix, sputum or rectum

MCS2

2089, 2090

Microscopy and culture of material from post-operative wounds, aspirations of body cavities, synovial fluid, CSF and operative or biopsy specimens

MCS3

2098, 2099

Microscopy and culture of sputum for mycobacteria

AFB

2119, 2120

Urine microscopy, culture, identification and sensitivity

UMCS

2127, 2128

DIVISION 4—IMMUNOLOGY

Specific IgG or IgE antibodies

ALLG

2259, 2260

Antibodies to Tissue Antigens:

Acetylcholine receptor

ARA

2271, 2274

Adrenal cell

ADR

2271, 2274

Cardiolipin

ACL

2271, 2274

Centromere

ACA

2271, 2274

\n```\n\n \nSCHEDULE 2—continued\n\n```html\n

Approved Item Name of Test in Schedule

Abbreviation

Item Numbers

Gliad in IgA

GLIA

2271, 2274

Gastric parietal cell

PCA

2271, 2274

Glomerular basement membrane

GBA

2271, 2274

Insulin Receptor Antibodies

INSA

2271, 2274

Intercellular Cement Substance of skin

ICCS

2271, 2274

Jo-1

JO1

2271, 2274

Keratin

KERA

2271, 2274

Liver/Kidney microsomes

LKA

2271, 2274

Mitochondria

MA

2271, 2274

Parathyroid cell

PTHA

2271, 2274

PM-1

PM1

2271, 2274

Reticulin

RCA

2271, 2274

SCL 70

SCL

2271, 2274

Skeletal muscle

SLA

2271, 2274

Skin basement membrane

SKA

2271, 2274

Smooth muscle

SMA

2271, 2274

Thyroid microsomal

TMA

2271, 2274

TSH Receptor Antibody test

TSHA

2271, 2274

Tissue antigens which are not listed above must be written in full

Antibodies to Nuclear Antigens—detection

ANA

2261, 2262

Antibodies to Nuclear Antigens—quantitation and Measurement of DNA Binding if Positive ANA

ANAP

2263, 2266

Antibodies to Extractable Nuclear Antigens—detection

ENA

2267, 2268

Antibodies to Extractable Nuclear Antigens— characterization of antibodies if positive ENA

ENAP

2269, 2270

Complement Total, C3 or C4

COM

2289, 2290

Other complements must be specified

HLA Typing, comprising A, B, C and DR Phenotypes

HLA

2321, 2322

HLA Typing, one or more antigens

HLAN

2323, 2324

Immunoglobulins G, A, M or D

IG

2245, 2246

Immunoglobulin G, Subclasses 1-4

SIGG

2255, 2256

Immunoglobulin E

IGE

2257, 2258

Leucocyte Fractionation

LF.

2313, 2314

Leucocyte Functional Tests

LFF

2315, 2316

Leucocyte Surface Markers to assess lymphoid populations

LSML

2317, 2318

Leucocyte Surface Markers in investigation of probable haematological malignancy

LSMH

2319, 2320

Mantoux Test

MANT

2325, 2326

Paraprotein Investigation by Immuno-electrophoreses or immunofixation

PPRO

2239, 2240

Paraprotein Investigation on Concurrently Collected Serum and Urine

PPSU

2241, 2242

Rheumatoid Factor (all tests including Latex test)

RF

2281, 2282

Rheumatoid Factor quantitation

RFQ

2283, 2284

DIVISION 5—HISTOPATHOLOGY

Electron microscopy of biopsy material

EM

2333, 2337

Histopathology of biopsy material

HIST

2327, 2328

Immediate frozen section diagnosis of biopsy material

FS

2329, 2330

\n```\n\n \nSCHEDULE 2—continued\n\n```html\n

Approved Item Name of Test in Schedule

Abbreviation

Item Numbers

Immunohistochemical investigation of biopsy material

IHIS

2331, 2332

DIVISION 6—CYTOPATHOLOGY

Cytology from cervix or vagina

CXCY

2338, 2339

Cytology from skin, nipple discharge, lip, mouth, nose or anus

SMCY

2340, 2341

Cytology from body fluids, sputum (1 specimen), washings or brushings

BFCY

2340, 2341

Cytology from 3 sputum or urine specimens

SPCY

2348, 2349

Cytology from fine needle aspiration of solid tissues

FNCY

2350, 2351

Cytology from fine needle aspiration of solid tissues— aspiration or attendance by Pathologist

FNCP

2355, 2356

DIVISION 7—CYTOGENETICS

Chromosome studies

CS

2360, 2361

Chromosome studies of blood

CSB

2363, 2364

Chromosome identification by banding techniques

CSI

2365, 2366

DIVISION 8—INFERTILITY AND PREGNANCY TESTS

Semen examination for spermatozoa

SES

2370, 2371

Huhner’s test

HT

2370, 2371

Semen examination

SEE

2372, 2373

Sperm antibodies

SAB

2377, 2378

Sperm penetrating ability

SPA

2377, 2378

Chorionic gonadotrophin for pregnancy diagnosis

HCG

2379, 2380

Chorionic gonadtrophin for diagnosis of specified conditions

HCGD

2384, 2385

\n```\n\nNOTE\n\n1\\. Notified in the Commonwealth of Australia Gazette on 12 October 1990.","sortOrder":0}],"analysis":{"kimi_summary":{"_metrics":{"model":"kimi-k2.5","source":"moonshot-realtime","completionTokens":1437},"content_quality":"ok","complexity_score":6,"scope_assessment":{"changed":false,"description":"This regulation performs exactly the technical variation of the pathology services table permitted by the Health Insurance Act 1973. It updates fees and service descriptions without expanding beyond the original legislative purpose of maintaining the Medicare pathology benefits schedule."},"complexity_factors":["Dense medical terminology requiring pathology expertise to interpret (e.g., 'Kleihauer test for HbF', 'alpha-naphthyl acetate esterase')","Dual fee structure (SP vs OP tiers) creating parallel payment pathways for the same tests","Cross-referencing between items where services 'include' or 'exclude' other numbered items","Temporal claiming restrictions (e.g., 'maximum of two estimations in any 12-month period')","Extensive abbreviation schedule with 100+ defined terms across 8 pathology divisions"],"plain_english_summary":"This instrument updates the Medicare Benefits Schedule for pathology: it adds and revises hundreds of test items and descriptions, establishes two fee tiers (Specialist and Other Pathologists), removes a few obsolete items, refreshes ordering abbreviations, and repeals two older statutory instruments. \n\nIt matters to patients (which tests get Medicare rebates and how much), pathologists and laboratories (their fees), and GPs/specialists (the billing codes they must use)."}},"importantCases":[],"_links":{"self":"/api/acts/health-insurance-variation-of-pathology-services-table-no-2-regulations","history":"/api/acts/health-insurance-variation-of-pathology-services-table-no-2-regulations/history","analysis":"/api/acts/health-insurance-variation-of-pathology-services-table-no-2-regulations/analysis","conflicts":"/api/acts/health-insurance-variation-of-pathology-services-table-no-2-regulations/conflicts","importantCases":"/api/acts/health-insurance-variation-of-pathology-services-table-no-2-regulations/important-cases","documents":"/api/acts/health-insurance-variation-of-pathology-services-table-no-2-regulations/documents"}}